Search
IGC Pharma Inc
IGCAdd to Watchlist
0.286USD
+0.003+1.06%
Close 09-23 16:00（ET）
29.85MMarket Cap
LossP/E TTM
After-hours 18:30 (ET)0.286USD0.000
After-hours 18:30 (ET)IGC Pharma Inc (IGC) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to IGC Pharma Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
4.000USD+1313.43%
IGC Analyst Recommendation Trends
In the current month, IGC has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IGC average Analyst price target in the last month is 4.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
1
IGC Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, IGC EPS is projected to reach -0.017 in FY2027Q1, following reported EPS of -0.024 in FY2026Q4. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q4
FY2026Q3
FY2027Q1
Forecast
--
-0.02
-0.02
-0.02
-0.02
Actual
-0.02
-0.02
-0.02
--
--
Surprise
--
-11.59%
-16.69%
--
--
FAQs
What is IGC Pharma Inc's expected revenue for the next quarter?
IGC Pharma Inc's expected revenue is 246.00K.
What is IGC Pharma Inc's price target?
Analysts forecast that IGC Pharma Inc's price target is USD 4.00, with the highest forecast at USD 5.00 and the lowest forecast at USD 3.00.
How have IGC Pharma IncIGC's recent earnings per share performed?
The market expectation was USD -0.02, while IGC Pharma IncIGC's earnings per share (EPS) for the previous quarter was USD -0.02. EPS for the next quarter is expected at USD -0.02.
What is the analyst rating for IGC Pharma Inc?
Based on the ratings of IGC Pharma Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.